{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-25-000031","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.535951+00:00","generated_at":"2026-05-17T01:31:01.218321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AptarGroup Q3 2025: adj. EPS $1.62 (+4% YoY); pharma injectables surge 18%; Q4 adj. EPS guidance $1.20-$1.28","bullets":["Reported sales $961M (+6% YoY); core sales +1%. Reported EPS $1.92 (+30%); adjusted EPS $1.62 (+4%).","Pharma injectables sales surged 18% driven by GLP-1 components; Pharma core sales +2%.","Beauty core sales flat; Closures core sales -1% due to lower tooling and resin pass-throughs.","Q4 adjusted EPS guidance $1.20-$1.28; returned $70M to shareholders in Q3 via repurchases and dividends."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-25-000031","json":"https://secwatch.observer/filing/0000896622-25-000031.json","markdown":"https://secwatch.observer/filing/0000896622-25-000031.md","text":"https://secwatch.observer/filing/0000896622-25-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662225000031/0000896622-25-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662225000031/atr-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:31:01.218321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}